2J·

Catalyst Pharmaceuticals Q2 Earnings

$CPRX (+0 %) 🚀💪


Catalyst Pharmaceuticals (NASDAQ: CPRX) reported second quarter EPS of $0.680, $0.29 more than the analyst estimate of $0.390.

Revenue for the quarter totaled $146.54M, compared to the average estimate of $140.22M.


Achieved Q2 2025 record total revenue of $146.6M, an increase of 19.4% year-over-year, marking another quarter of consecutive growth

Reported record revenue for the first half of 2025 of $288.0 million, an increase of 30.2% year-on-year

Confirms full-year 2025 total sales guidance of $545 million to $565 million, reflecting broad-based growth and continued demand

FIRDAPSE® Q2 2025 net product sales of $84.8 million, up 9.7% YoY; net product sales of $168.6 million in the first half of 2025, up 16.9% YoY, highlighting continued momentum and confidence in long-term growth

AGAMREE® Q2 2025 net product sales of USD 27.4 million, 212.9% year-on-year; net product sales of USD 49.4 million in the first half of 2025, an increase of 398.0% year-on-year, underlining continued product momentum

FYCOMPA® Q2 2025 net product sales of USD 34.3 million; slight decrease in prior year due to generic entry following loss of exclusivity

Strong cash position of USD 652.8 million and no funded debt at the end of Q2 2025

attachment
attachment
6
2 Commentaires

Never heard of $CPRX, but it seems very interesting 👀
Any idea why it's dropping so hard...? I saw some comments about the fact that this company is not really a growth company, rather a margins company. But down 10% with such numbers... I don't understand.
Participez à la conversation